الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 187 |  |  |
| | | from | 187 | | |
Abstract
Bovine respiratory disease (BRD) is one of the most serious diseases counted for
economic loss and extensive usage of antibiotics in cattle. Ceftiofur, third-generation
cephalosporin antibiotic, has been approved for use in cattle in the United States. This
study was done to investigate the clinical effect of ceftiofur on calves as well as its
efficacy and safety for treating BRD.
Thirty Holstein calves in a dairy farm were divided in to 3 equal groups. group I
was utilized as a healthy negative group. group II was composed of healthy animals
injected with ceftiofur (2mg/kg B.W) subcutaneously in the ear as single dose. Group
III, clinically investigated to be suffering from BRD, was given ceftiofur with the same
dose and administration route as group II.
All groups were clinically evaluated at day 0, 7, and 14 after drug administration
for illness score, body weight, body gain, feed intake, body temperature, depression
score, discharges, coughing score and lung score.
Clinical illness score showed clear signs of BRD (elevation of body temperature
and depression). Nasal, ocular and ear discharges were recorded and ranked.
Significant increases in respiratory and coughing score were observed in diseased
calves. Significant increase in the lung score. Additionally, significant changes in the
hematological and biochemical analysis.
group III showed a significant decrease in the body weight, body gain and food
intake compared to other groups. Non-significant changes between groups I and II
were evaluated.
It is clearly concluded that ceftiofur could be the drug of choice for treating BRD
due to its high efficacy, low adverse effects on clinical signs, and suitability of dosing
and administration also negative effect on the liver and kidney function.